Next Article in Journal
Biocompatibility of Genipin and Glutaraldehyde Cross-Linked Chitosan Materials in the Anterior Chamber of the Eye
Next Article in Special Issue
Tissue Microarray-Based Evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as Tumour Prognostic Marker
Previous Article in Journal
Gamma Irradiation of in-Shell and Blanched Peanuts Protects against Mycotoxic Fungi and Retains Their Nutraceutical Components during Long-Term Storage
Previous Article in Special Issue
Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(9), 10959-10969;

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians

Institute of Pathology, University Hospital Erlangen, Erlangen 91054, Germany
University Clinic of Urology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91054, Germany
Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg 93053, Germany
Institute of Pathology, University of Regensburg, Regensburg 93053, Germany
Author to whom correspondence should be addressed.
Received: 26 July 2012 / Revised: 14 August 2012 / Accepted: 27 August 2012 / Published: 31 August 2012
(This article belongs to the Special Issue Advances in Molecular Oncology (special issue))
Full-Text   |   PDF [521 KB, uploaded 19 June 2014]


NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyses the reduction of quinoid compounds to hydroquinones, preventing the generation of free radicals and reactive oxygen. A “C” to “T” transversion at position 609 of NQO1, leading to a nonsynonymous amino acid change (Pro187Ser, P187S), results in an altered enzyme activity. No NQO1 protein activity was detected in NQO1 609TT genotype, and low to intermediate activity was detected in NQO1 609CT genotype compared with 609CC genotype. Thus, this polymorphism may result in altered cancer predisposition. For prostate cancer, only sparse data are available. We therefore analyzed the distribution of the NQO1 P187S SNP (single nucleotide polymorphism) in prostate cancer patients and a healthy control group. Allelic variants were determined using RFLP analysis. Overall, 232 patients without any malignancy and 119 consecutive prostate cancer patients were investigated. The genotype distribution in our cohorts followed the Hardy–Weinberg equilibrium in cases and controls. The distribution of the NQO1 codon 187 SNP did not differ significantly between prostate cancer patients and the control group (p = 0.242). There was also no association between the allelic variants and stage or Gleason score of the tumors. The NQO1 P187S SNP was not significantly associated with an increased prostate cancer risk in our cohorts. The SNP has also no influence on histopathological characteristics of the tumors. A combined analysis of all available data from published European studies also showed no significant differences in the genotype distribution between controls and prostate cancer patients. Our data suggest a minor role of the NQO1 nucleotide 609 polymorphism in prostate carcinogenesis. View Full-Text
Keywords: prostate cancer; NQO1; case-control study; restriction fragment length polymorphism analysis prostate cancer; NQO1; case-control study; restriction fragment length polymorphism analysis
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Stoehr, C.G.; Nolte, E.; Wach, S.; Wieland, W.F.; Hofstaedter, F.; Hartmann, A.; Stoehr, R. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians. Int. J. Mol. Sci. 2012, 13, 10959-10969.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top